Panagora Asset Management Inc. Reduces Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Panagora Asset Management Inc. decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 23.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 87,699 shares of the medical equipment provider's stock after selling 27,533 shares during the period. Panagora Asset Management Inc. owned approximately 0.13% of Lantheus worth $5,437,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of LNTH. Tucker Asset Management LLC boosted its position in shares of Lantheus by 239.0% during the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 282 shares in the last quarter. Principal Securities Inc. acquired a new stake in shares of Lantheus during the 4th quarter worth approximately $28,000. Covestor Ltd increased its stake in shares of Lantheus by 62.7% in the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 203 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Lantheus by 36.6% during the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider's stock valued at $40,000 after acquiring an additional 156 shares during the period. Finally, NBC Securities Inc. bought a new position in Lantheus during the third quarter worth $46,000. Institutional investors own 99.06% of the company's stock.

Insider Activity at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business's stock in a transaction on Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the transaction, the chief accounting officer now owns 62,898 shares of the company's stock, valued at $4,836,227.22. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares of the company's stock, valued at approximately $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the transaction, the chief accounting officer now owns 62,898 shares in the company, valued at approximately $4,836,227.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 94,545 shares of company stock valued at $6,177,295. 1.50% of the stock is owned by insiders.

Lantheus Stock Down 1.8 %

NASDAQ LNTH traded down $1.43 on Friday, reaching $79.67. The company had a trading volume of 950,979 shares, compared to its average volume of 1,055,360. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $5.52 billion, a P/E ratio of 12.16 and a beta of 0.52. The company's fifty day moving average is $65.20 and its 200 day moving average is $63.49. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $100.48.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating analysts' consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The company had revenue of $354.00 million for the quarter, compared to analyst estimates of $350.44 million. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. B. Riley lifted their price target on shares of Lantheus from $95.00 to $99.00 and gave the company a "buy" rating in a research note on Thursday, April 18th. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a research note on Friday, May 3rd. Truist Financial raised their price objective on Lantheus from $82.00 to $96.00 and gave the company a "buy" rating in a research note on Friday, May 3rd. Mizuho upped their target price on Lantheus from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, May 3rd. Finally, JMP Securities reissued a "market outperform" rating and issued a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and an average price target of $99.17.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.